Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma

Phyllis A. Gimotty; Jacob E. Till; Shirsa Udgata; Naomi Takenaka; Stephanie S. Yee; Michael J. LaRiviere; Mark H. O’Hara; Kim A. Reiss; Peter O’Dwyer; Bryson W. Katona; Daniel Herman; Erica L. Carpenter; Kenneth S. Zaret

doi:10.18632/oncotarget.28127

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma

PDF | How to cite

Oncotarget. 2022; 13:1187-1187. https://doi.org/10.18632/oncotarget.28127

Metrics: PDF 582 views | ?

Phyllis A. Gimotty^1,*, Jacob E. Till^2,*, Shirsa Udgata³, Naomi Takenaka³, Stephanie S. Yee², Michael J. LaRiviere⁴, Mark H. O’Hara², Kim A. Reiss², Peter O’Dwyer², Bryson W. Katona⁵, Daniel Herman⁶, Erica L. Carpenter^2,** and Kenneth S. Zaret^3,**

¹Division of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
²Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
³Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
⁴Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
⁵Division of Gastroenterology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
⁶Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
^*These authors contributed equally to this work
^**Co-corresponding authors

Published: November 2, 2022

Copyright: © 2022 Gimotty et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Authors Kenneth S. Zaret and Erica L. Carpenter contributed equally as corresponding authors. The footnote to the author list indicating both individuals as co-corresponding authors was unintentionally omitted. The proper footnote is shown below:

** Co-corresponding authors

In addition, the paper’s title has been corrected to read, ‘THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma.’ The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2021; 12:2266–2272. DOI: https://doi.org/10.18632/oncotarget.28099

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28127

Publication Alerts

Corrections:

Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma